10.05.16 -- The Price At My CMO Isn't Right ... But How Do I Know?

By Louis Garguilo, Chief Editor, Outsourced Pharma

"What we're doing up here is never done – focusing on that one input in public. Instead of focusing on money, you talk openly about ‘value.' Well, what is that? Or it's all about ‘relationships.' The industry talks partnership in public, but behind closed doors, aren't prices and costs closing or breaking outsourcing business deals?"

White Paper | By Devon DuBose, Dana Settell, Nathan Bennette, and Amber Broadbent, Ph.D.

A significant share of current drug development pipelines include active pharmaceutical ingredients (APIs) that fall into BCS (biopharmaceutical classification system) 2 and 4 spaces. These compounds are typically characterized by their low aqueous solubility and thus poor bioavailability, requiring advanced formulation approaches. Various approaches have been developed to enable these types of compounds, including particle size reduction (e.g., micronization), chemical modification (e.g., salt forms and pro-drugs), complexing agents, solubilized liquid forms (e.g., SEDDS), and solid amorphous dispersions.

White Paper | By Paul Dupont, VP, Marketing and Business Development, Ropack Pharma Solutions

With the stakes higher than ever for drug sponsors, choosing a CDMO that is the best strategic fit is not just difficult, but imperative. These "three Cs" can indicate whether a CDMO has the ability to provide a drug sponsor with not only the resources to fulfill a company's long-term goals but also the confidence that every team member involved is committed to its success.

Article | By John Ward, Vice President, Engineering, Patheon

With more complex molecules in development, changing capacity needs, uncertain forecasts, and increased competition, the market demands flexibility and innovative approaches to address today's new challenges.

Video | CRF Health

Adopting a patient-centric focus in your trial is known to lead to more engaged patients and higher quality, more accurate clinical data. In this short three-minute video we explore how electronic clinical outcomes assessment (eCOA) technology is revolutionizing the clinical trial experience for patients and sites — helping sponsors to easily overcome the toughest challenges of paper-based data collection.

Patheon

Phillips-Medisize

For insight on how pharma and biopharm executives can improve how they run their businesses, subscribe to Life Science Leader magazine.